Signosis has established the Jak2 V617F + EPOR expressing Ba/F3 cell line that faithfully recapitulates both ligand-dependent and ligand-independent JAK2 signaling, closely resembling polycythemia vera. This line enables detailed mechanistic studies of JAK2-EPOR interactions, robust STAT activation, and full cytokine-independent proliferation, providing an optimized platform for therapeutic screening and oncogenic transformation research.
 
The cell line was generated by co-expressing JAK2 V617F with EPOR in a single vector in BaF3 cells, and the single clones have been selected with hygromycin treatment and GFP expression. The positive clone has been confirmed with PCR-sequencing and Western blot with anti-JAK antibody and anti-EPOR antibody.